PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors
Abstract Background Programmed death-ligand 1 (PD-L1) inhibitors has emerged as a first-line therapeutic strategy for advanced small cell lung cancer (SCLC), which can stimulate T-cell activation, thereby preventing tumor avoidance of immunologic surveillance, whereas, proton pump inhibitors (PPIs)...
| Prif Awduron: | , , , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
BMC
2023-11-01
|
| Cyfres: | BMC Pulmonary Medicine |
| Pynciau: | |
| Mynediad Ar-lein: | https://doi.org/10.1186/s12890-023-02754-4 |